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Looking for BRPF1 Presence in Differentiating Osteoclast Cells
Mark Birnbaum, Nicholas Khoury
Abstract: 
Through this semester-long experiment, 
professor Birnbaum and I attempted to 
identify the presence of BRPF1 
(Bromodomain And PHD Finger 
Containing 1) in harvested RAW 
osteoclast cells. This was done through 
a series of steps, beginning with 
growing RAW osteoclasts, differentiating 
them, harvesting them and finally 
running a Western Blot test to look for 
our target protein. Unfortunately, no 
major discoveries were made with this 
project, but there is still reason to be 
optimistic about the presence of other 
members of the BRPF family (BRPF3, 
BRPF4). With some knowledge on our 
procedure, future researchers should be 
able to note specific points that could be 
tweaked for improvement to yield better 
results. 
Introduction: 
This research was done as a part of my 
senior thesis in conjunction with the 
Honors Program at Merrimack College. 
The results of this research paper were 
disseminated at the Research and 
Creative Achievement Conference on 
campus. Through this semester long 
research, professor Birnbaum and I built 
upon the research we had done of 
BRPF proteins in his Cellular Biology 
class the previous semester. BRPF1 is 
a protein that in humans is encoded by 
the BRPF1 gene located on 3p26-p25. It 
is a multivalent chromatin regulator that 
recognizes different epigenetic marks 
and activates three histone 
acetyltransferases (Moz, Morf and 
Hbo1). BRPF1 contains two PHD 
fingers, one bromodomain and one 
chromo/Tudor-related Pro-Trp-Trp-Pro 
(PWWP) domain. This gene is very 
conserved and has a critical role in 
different developmental processes of 
embryos as well as with tumors, which 
is what interested us the most. Brpf1 
was reported to have a tumor 
suppressing role in malignant tumors. 
This conclusion was based on the 
observation that mutations in cancer 
cells appeared to diminish the function 
of Brpf1. However, oncogenic role of 
Brpf1 is also possible in cancer, as it 
can form a stable complex with Moz-
Tif2, which could lead to the 
development of leukemia in humans. 
So, by looking for this gene’s presence 
in RANKL treated osteoclast cells, we 
aimed to confirm its role in osteoclast 
differentiation, which could be important 
for future studies concerning BRPF1’s 
role in osteoclast differentiation and 
tumor suppression/promotion. While 
studies have shown the RNA for BRPF1 
being present in differentiating 
osteoclast cells, no one has ever 
confirmed the presence of BRPF1 
protein itself. 
Materials and Methods: 
Osteoclast growth and differentiation 
using RANKL procedure: First, we 
diluted 45 μL of cell media that was 
combined with 5 μL of cells with 14 mL 
of 20% fetal bovine serum (FBS) and 
left the cells to incubate for 3 days on 
one culture plate. Next, we divided the 
cells in half and dispersed the 7 mL 
portions between two larger culture 
plates with fresh media to ensure we 
had enough osteoclasts to work with. 
Then, after a week of growth and re-
feeding (replacing 7 mL of old media 
with new media every two days), the 
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cells were refed one last time, but only 
with 5 mL of media. The plate was then 
scraped and stirred to suspend the cells 
in fluid, and a portion of this mixture was 
removed and counted under a 
microscope using a hemocytometer and 
tryptophan blue stain to predict the total 
number of cells/mL of fluid. The 
approximate number came out to 
2,400,000 cells/mL in our counting. We 
then calculated .125 μL + 10 mL to 
achieve a diluted sample of 30,000 
cells/mL. Upon diluting and observing 
the diluted cells, they seemed too thin, 
so we combined 250 μL of cells from 
stock with 10 mL of media to achieve a 
diluted sample of 60,000 cells/mL. This 
combination of cells and media was 
then put in one well of a multi-well plate 
and incubated. After confirming 
sufficient growth two days later, the cells 
were re-fed with fresh media and 
combined with 2 μL of receptor activator 
of nuclear factor kappa-Β 
ligand (RANKL) per well. RANKL is a 
key osteoclast differentiation factor, so 
we expected to see differentiation after 
three more days of incubation. After 
three days, a portion of the cells were 
again stained with tryptophan blue and 
observed under a microscope using a 
hemocytometer. The cells seemed far 
too dilute upon this observation (no 
more than 5 cells per 4x4 grid could be 
seen). It was apparent that the cells 
needed to be re-plated and re-fed with 
fresh media, given one more week to 
grow, and be diluted to a lesser degree. 
After observing these new cells once 
more under a microscope, they were re-
fed and re-plated by putting 2.5 mL of 
the cell and stock solution into three 
new wells on the multi-well plate. This 
gave us four total wells, which we 
labeled as day 0 thru day 3 for 
harvesting. Day 0 was able to be 
immediately harvested, as this was the 
start of our 4-day interval. 
Cell harvesting procedure: To harvest 
the cells from their plates, we first set up 
a plastic tube and put 1 protease 
inhibitor tablet in it. To this we added 10 
mL Radioimmunoprecipitation assay 
(RIPA) Buffer and vortexed it until the 
tablet had completely dissolved in 
solution. Next, the well with the cells to 
be harvested had its media removed 
and it was washed with 2 mL of 
Phosphate-buffered saline (PBS). The 
PBS was then immediately removed 
and 250 μL of RIPA Buffer was added to 
the well. This plate was then vigorously 
scraped to ensure all cells were 
suspended in solution before the 
solution was removed and placed in an 
Eppendrof tube. This tube, containing 
harvested RAW osteoclast cells that had 
been treated with RANKL was our day 0 
sample. The tube was placed in a -80 
degree centigrade chiller for storage to 
prevent denaturation until we were 
ready to work with them again. Over the 
next 3 days, the harvesting process was 
repeated on the subsequent three plates 
to give us day 1, day 2 and day 3 
samples. The next step was to run a 
protein assay, which required a PierceTM 
BCA Protein Assay Kit. 
Protein assay procedure: First, a 
preparation of Diluted Albumin (BSA) 
Standards had to be made. This was 
done by diluting the contents of one 
BSA ampule into several clean vials 
(using the same diluent as the sample). 
Each 1 mL ampule of 2 mg/mL BSA was 
sufficient to prepare a set of diluted 
standards for a working range of 25-
2,000 μg/mL concentration. First, vials 
labeled A-I loaded with the BSA were 
given specified amounts of diluent, 
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shown in figure 1.1 below. Next, vials A-
C were given different amounts of stock 
solution, vials D-H were given dilutions 
from other vials and vial was left without 
any stock/BSA dilution. Upon doing this, 
a ladder could now be made with BSA 
concentrations ranging from 25- 2,000 
μg/mL. 
Fig. 1.1
Next, a preparation of BCA working 
reagent (WR) was made using the 
formula (# standards + # unknowns) x 
(#replicants) x (volume of WR per 
sample) = total volume WR required. 
The WR reagents were prepared by 
mixing 50 parts of BCA Reagent A with 
1 part of BCA Reagent B. 2.0 mL of this 
working reagent was added to.1 mL of 
both the sample to be assayed in a and 
with the appropriate BSA standard in a 
test tube, Next, the solution in the test 
tubes was able to be transferred to 
cuvettes and run through the 
spectrophotometer (along with a blank 
for control) to yield an absorbance rate 
at 562 nm wavelength. Results of this 
test can be seen in fig 1.2 in the results 
section. Day 3 harvested osteoclasts 
were initially observed to have 
extremely low protein levels, so a new 
set of osteoclasts had to be treated with 
RANKL and incubated for 3 days before 
another day 3 sample could be pulled 
and run through the spectrophotometer. 
Once we had appropriate absorbance 
readings for protein presence in all four 
of our samples (day 0- day 3), we were 
able to move onto preparation for the 
Western Blot. 
Western Blot Procedure: To execute 
the final step of our procedure, the 
Western Blot, we first needed to run an 
electrophoresis gel. During the 
electrophoresis, our negatively charged 
proteins moved toward the positively 
charged anode, which is what 
propagates proteins in any gel to move 
down through the gel. Our samples 
were prepared and loaded onto a gel, 
along with a standard protein ladder that 
gave us a benchmark of where proteins 
would end up on the gel based on their 
size. This ladder ranged from 250 kDa 
to 25 kDa. In order to further analyze the 
proteins after they had completed a 
sufficient run time (we knew it weighed 
137 kDa, so we looked at the standard 
that weighed 150 kDa and waited for 
that to run approximately half way down 
the gel), they were transferred onto a 
membrane in a procedure called 
blotting. This was done by putting the 
gel on top of a membrane for transfer, 
between two buffer-soaked filter sheets 
(in order to prevent unwanted 
membrane-protein interaction in the 
following steps) and finally on the anode 
floor of the blotting machine where it 
was covered by a cathode plate and 
allowed to run. To visualize our protein 
of interest after the transfer was 
complete, the membrane was first 
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washed with TBST without milk, then it 
was probed using a primary protein-
specific antibody with TBST and milk 
with washes in between. Once this had 
been applied, we applied a labeled 
secondary antibody that would reveal 
our target protein if it was present on the 
membrane. 
Results: Seen in fig. 1.2 are the results 
of our protein assay, which gave us a 
good measurement of exactly how much 
protein we had in our day 0- day 3 
samples. Using an excel spreadsheet, 
we were able to make a graph from the 
BSA concentration ladder. Off of the 
protein concentration vs standard 
protein average absorbances at 562 nm, 
we could determine where on the graph 
our protein would fall, given its 
absorbance at 562 nm. This was done 
by using every second number (in red) 
in column A, standard protein 
absorbance @ 562 nm, except for the 
last number in the column, where the 
first number in red was used instead 
(1.944, here we used 1.489 instead 
because it stayed in bounds on our 
trend line). Every first number in column 
A represents a cuvette that contained 20 
μL of our cell solution, and every second 
number represents a cuvette that 
contained 100 μL of our cell solution.  
The resulting concentrations of our 
proteins went as follows: day 0 had a 
concentration of 495 μg/mL, day 1 had a 
concentration of 660 μg/mL, day 2 had a 
concentration of 950 μg/mL and day 3 
had a concentration of 1450 μg/mL. 
Initial day 3 harvested osteoclasts (not 
shown) were redone because they gave 
us a 20 μL reading of .008 absorbance, 
and a 100 μL reading of .027 
absorbance, which would correlate to a 
concentration less than 100 μg/mL 
based on our standard graph. 
Fig 1.2
As displayed in fig. 1.3, there is a 
questionable indication of the BRPF1 
protein on this Western Blot. We see our 
protein standard ladder in the lane on 
the far right, but there is no definitive 
indication of BRPF1 presence anywhere 
else on this membrane. From left to 
right, we expected to see lines 
somewhere between the second and 
third standard lines on the ladder. The 
second standard line translated to a 
molecular weight of about 150 kDa, and 
the third line translated to a molecular 
weight of about 100 kDa. The molecular 
weight of BRPF1 is approximately 137 
kDa, meaning it theoretically should 
have fallen somewhere between these 
two lines. Furthermore, we hypothesized 
to notice a pattern from left to right of 
the BRPF1 containing bands getting 
darker. This would have signified that as 
time went on (from day 0 to day 3) there 
was differentiation occurring in the 
osteoclasts that promoted further 
expression of the BRPF1. Instead of 
seeing these results, though, we instead 
saw two lines (that got fainter from day 1 
to day 2). Circled in figure 1.3 are these 
two possible bands that we found on 
this membrane, but its reliability is 
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debatable. The faintly observable band 
is not near its supposed molecular 
weight of 137 kDA, but rather up near 
the top line of the ladder, which signifies 
a molecular weight somewhere around 
250 kDA. While this is a highly unlikely 
position for the protein to be positioned 
at, considering that the standard ladder 
run on the right side of the membrane 
ran reliably and without any problems, it 
is a possibility that this is BRPF1. We 
can say this because we used a protein 
specific antibody, meaning the antibody 
was tailored to only stick to BRPF1 and 
nothing else. Further testing would be 
required to confirm or deny this oddly 
placed location of the visible band on 
our membrane. 
Fig 1.3
Conclusion: While we were not able to 
get the exact results we hypothesized to 
see, this does not mean that there is no 
BRPF1 to be found in osteoclasts. The 
presence of its RNA still supports the 
proteins presence and the two bands 
that we did see on the gel means we 
cannot confidently rule out the incidence 
of BRPF1 in our differentiated 
osteoclasts. There could be some 
procedural changes to make that might 
confirm or deny our initial hypothesis to 
a greater degree. Some reasons for our 
potential inability to find the protein 
could be dilution beyond a threshold of 
observability. Having to regrow and 
harvest our day 3 samples was also an 
inconvenience, as it gave us two 
separately grown sets of osteoclasts 
(day 0- day 2 and day 3). For 
consistency in experiments like this, it is 
always preferred to have all the cells 
come from one batch to minimize 
potential error. The largest source of 
error was likely related to these 
technical details. Simply put; there might 
not have been enough cells, meaning 
there wasn’t enough protein to give us 
an accurate reading. This could go back 
to the dilution of our cells (to an initial 
dilution of 30,000 cells/mL and then to 
60,000 cells/mL). To garner higher 
protein and cell density, more cells 
could have been initially added. 
However, one must be careful to not 
grow too many cells because this might 
cause overcrowding, which means that 
the osteoclasts won’t differentiate. Next 
semester, Professor Birnbaum will 
tackle this research with another student 
to try and get more comprehensive 
results and draw a more definite 
conclusion on our experiment.
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